Glaucoma Market Development of New Drugs and Therapies 2017 to 2021


    Glaucoma is a group of eye diseases which result in damage to the optic nerve and vision loss. The most common type is open-angle glaucoma with less common types including closed-angle glaucoma and normal-tension glaucoma. Open-angle glaucoma develops slowly over time and there is no pain. Side vision may begin to decrease followed by central vision resulting in blindness, if not treated. Closed-angle glaucoma can present gradually or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea. Vision loss from glaucoma, once it has occurred, is permanent.

    Though, glaucoma cannot be cured completely but the disease progression can be controlled with the help of available treatments. There are three types of modalities available for treatment of glaucoma: Drugs, Laser and Invasive Surgery. Further, based upon the approaches employed for the medication, it can be segmented into two parts: PGA Medication and Non-PGA Medication. The PGA approach reduces IOP with the help of prostaglandin (PGA). The non-PGA medication can be further divided into four sub segments: Beta blockers, Alpha blockers, Carbonic anhydrase inhibitors (CAIs) and Combination Products.

    Several factors such as rising prevalence of diabetes, growing geriatric population and rising health care expenditure along with increasing disposable income and growing obese population will drive the market growth in the next few years. Development of new drugs & devices and drug therapy focused upon IOP are the few notable market trends. However, high cost of treatment, severe side effects and hasty drug approval processes act as a major roadblock for the market growth.

    Avail Complete research data at:

    The report “Global Glaucoma Market: Industry Analysis & Outlook (2017-2021)” analyzes the development of this market, with focus on the US and OUS treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Pfizer Inc., Novartis AG, Merck & Co., Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global glaucoma market along with the study of the US market.

    Browse Full Report at:

    Essential Points Covered in List of Charts are: 

    • Global Glaucoma Market Forecast by Value (2016-2021)
    • Global Glaucoma Drugs Market Forecast by Value (2016-2021)
    • Global Glaucoma Patient Volume Forecast (2016-2021)
    • The US Open Angle Glaucoma Patient Volume Forecast (2016-2021)
    • The US Glaucoma First Line Drugs Prescription Volume Forecast (2016-2021)
    • Global Type 2 Diabetes Patients Population Forecast (2016-2021)
    • The US Glaucoma First Line Drugs Market Share by Company (2016/2021)
    • The US MIGS Market Share by Company (2016/2021)
    • Novartis AG Net Sales and Net Income (2012-2016)